TY - JOUR
T1 - The extremophilic actinobacteria
T2 - From microbes to medicine
AU - Hui, Martha Lok-Yung
AU - Tan, Loh Teng-Hern
AU - Letchumanan, Vengadesh
AU - He, Ya-Wen
AU - Fang, Chee-Mun
AU - Chan, Kok-Gan
AU - Law, Jodi Woan-Fei
AU - Lee, Learn-Han
N1 - Funding Information:
This work was supported by SEED Funding from Microbiome and Bioresource Research Strength (MBRS), Jeffrey Cheah School of Medicine and Health Sciences (Vote Number: MBRS/JCSMHS/02/2020), JCSMHS Strategic Grant 2021 (Grant Code: STG-000051), University of Malaya Research Grant (FRGS grant to K-GC grant no: FP022-2018A), and Fundamental Research Grant Scheme (FRGS/1/2019/SKK08/MUSM/02/7).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/6
Y1 - 2021/6
N2 - Actinobacteria constitute prolific sources of novel and vital bioactive metabolites for pharmaceutical utilization. In recent years, research has focused on exploring actinobacteria that thrive in extreme conditions to unearth their beneficial bioactive compounds for natural product drug discovery. Natural products have a significant role in resolving public health issues such as antibiotic resistance and cancer. The breakthrough of new technologies has overcome the difficulties in sampling and culturing extremophiles, leading to the outpouring of more studies on actinobacteria from extreme environments. This review focuses on the diversity and bioactive potentials/medically relevant biomolecules of extremophilic actinobacteria found from various unique and extreme niches. Actinobacteria possess an excellent capability to produce various enzymes and secondary metabolites to combat harsh conditions. In particular, a few strains have displayed substantial antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), shedding light on the development of MRSA-sensitive antibiotics. Several strains exhibited other prominent bioactivities such as antifungal, anti-HIV, anticancer, and anti-inflammation. By providing an overview of the recently found extremophilic actinobacteria and their important metabolites, we hope to enhance the understanding of their potential for the medical world.
AB - Actinobacteria constitute prolific sources of novel and vital bioactive metabolites for pharmaceutical utilization. In recent years, research has focused on exploring actinobacteria that thrive in extreme conditions to unearth their beneficial bioactive compounds for natural product drug discovery. Natural products have a significant role in resolving public health issues such as antibiotic resistance and cancer. The breakthrough of new technologies has overcome the difficulties in sampling and culturing extremophiles, leading to the outpouring of more studies on actinobacteria from extreme environments. This review focuses on the diversity and bioactive potentials/medically relevant biomolecules of extremophilic actinobacteria found from various unique and extreme niches. Actinobacteria possess an excellent capability to produce various enzymes and secondary metabolites to combat harsh conditions. In particular, a few strains have displayed substantial antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA), shedding light on the development of MRSA-sensitive antibiotics. Several strains exhibited other prominent bioactivities such as antifungal, anti-HIV, anticancer, and anti-inflammation. By providing an overview of the recently found extremophilic actinobacteria and their important metabolites, we hope to enhance the understanding of their potential for the medical world.
KW - Actinobacteria
KW - Bioactivity
KW - Environment
KW - Extremophile
KW - Metabolites
UR - http://www.scopus.com/inward/record.url?scp=85108551725&partnerID=8YFLogxK
U2 - 10.3390/antibiotics10060682
DO - 10.3390/antibiotics10060682
M3 - Review Article
C2 - 34201133
AN - SCOPUS:85108551725
VL - 10
JO - Antibiotics
JF - Antibiotics
SN - 2079-6382
IS - 6
M1 - 682
ER -
